ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "chemokines"

  • Abstract Number: 0514 • ACR Convergence 2021

    Extracellular Sulfatase-2 Mediates TNF-α Inflammatory Signaling in Human Rheumatoid Arthritis Synovial Fibroblasts

    Ruby Siegel1, Anil singh1, Judy Vinh1, H. Mark Kenney2, Edward Schwarz3, David Fox4, Sadik Khuder5 and Salah-uddin Ahmed1, 1Washington State University, Spokane, WA, 2University of Rochester Medical Center, Rochester, NY, 3University of Rochester, Rochester, NY, 4Division of Rheumatology, University of Michigan Medical School, Ann Arbor, MI, 5Department of Medicine and Public Health, University of Toledo,, Toledo, OH

    Background/Purpose: TNF-α drives RA synovial fibroblast (RASF)-mediated hyperplasia and joint tissue destruction. Extracellular sulfatase-2 (Sulf-2) influences receptor/ligand binding and subsequent signaling of chemokines, cytokines, and…
  • Abstract Number: 0515 • ACR Convergence 2021

    The Extracellular Sulfatase-2 Inhibitor OKN-007 Abrogates TNF-α-induced Inflammatory Mediators in Human Rheumatoid Arthritis Synovial Fibroblasts

    Ruby Siegel, Sang Han and Salah-uddin Ahmed, Washington State University, Spokane, WA

    Background/Purpose: Recent unpublished findings from our lab show that the extracellular enzyme sulfatase-2 (Sulf-2) facilitates pro-inflammatory TNF-α signaling which activates rheumatoid arthritis synovial fibroblasts (RASFs).…
  • Abstract Number: 1365 • ACR Convergence 2021

    Release of High-Mobility Group Box-1 After an Raynaud’s Attack Potentially Leads to Fibroblast Activation and Interferon-γ Induced Protein-10 Production in Systemic Sclerosis

    Isabella Atzeni1, Yehya Al-Adwi2, Berber Doornbos-van der Meer2, Amel Eman Abdulle2, Anniek Van Roon2, Alja J. Stel2, Harry Van Goor2, Andries Smit2, Johanna Westra2 and Douwe J Mulder2, 1University of Groningen, University Medical Centre Groningen, Groningen, Groningen, Netherlands, 2University of Groningen, University Medical Centre Groningen, Groningen, Netherlands

    Background/Purpose: Raynaud’s Phenomenon (RP) leading to repetitive ischaemia and reperfusion (IR) stress, is the first recognisable sign of systemic sclerosis (SSc). Although RP has been…
  • Abstract Number: 0644 • ACR Convergence 2020

    Characterizations of Cytokine Storm Associated with COVID19

    Ofer Perzon1, Avi Abutbul1, Sigal Sviri1 and Dror Mevorach1, 1Hadassah-University Hospital, Jerusalem, Yerushalayim, Israel

    Background/Purpose: COVID-19, the name given to the clinical syndrome associated with the newly recognized virus SARS-CoV-2 has become pandemic with mortality estimated based on reports…
  • Abstract Number: 0682 • ACR Convergence 2020

    Role of Inflammatory and Oxidative Stress Pathway Biomarkers in Renal Disease in Gout

    Fatima Alduraibi1, Karina Ricart1, Rakesh Patel1, Alexander Szalai1, Joshua Melnick2 and Jasvinder Singh1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham (UAB), Vestavia Hills, AL

    Background/Purpose: To understand the role of inflammatory cytokines and oxidative stress biomarkers in the renal disease in people with gout. We hypothesized that higher gout…
  • Abstract Number: 0999 • ACR Convergence 2020

    CXCL13 Is a Key Driver for Migration and Differentiation of Regulatory B Cells

    Claire Rempenault1, Julie Mielle2, Kristina Schreiber1, Pierre Corbeau3, Jacques Morel4, Claire Daien4 and Rachel Audo2, 1Rheumatology, Montpellier, France, 2Institut de génétique moléculaire de Montpellier (IGMM), Montpellier, France, 3immunology, Nimes, France, 4Rheumatology department, CHU Montpellier and University of Montpellier, Montpellier, France

    Background/Purpose: Human regulatory B cells still need to be characterized. Given the absence of phenotypical definition, a functional definition based on their ability to secrete…
  • Abstract Number: 1150 • ACR Convergence 2020

    Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis

    Arianna De Matteis1, Denise Pires Marafon1, Ivan Caiello1, Manuela Pardeo1, Giulia Marucci1, Emanuela Sacco1, Giusi Prencipe1, Fabrizio De Benedetti2 and Claudia Bracaglia1, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 2Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy

    Background/Purpose: Macrophage Activation Syndrome (MAS) and secondary Hemophagocytic Lymphohistiocytosis (sHLH) are hyperinflammatory conditions caused by a cytokine storm, in which IFNγ plays a pivotal role.…
  • Abstract Number: 1523 • ACR Convergence 2020

    Pulmonary Cytokine, Chemokine and Growth Factor Profiles of Distinct Radiographic Patterns of Interstitial Lung Disease in Systemic Sclerosis

    Elizabeth Volkmann1, Donald Tashkin2, Ning Li2, Mei Leng2, Grace Kim2, Jonathan Goldin2, Airi Harui2 and Michael Roth2, 1University of California, Los Angeles, Los Angeles, CA, 2University of California, Los Angeles, Los Angeles

    Background/Purpose: The radiological hallmarks of systemic sclerosis-related interstitial lung disease (SSc-ILD) include interstitial inflammation (ground glass opacity) with reticular changes (fibrosis). The precise pathobiology of…
  • Abstract Number: 1528 • ACR Convergence 2020

    Filgotinib Inhibits Monocyte Differentiation and Pro Inflammatoly Cytokine Production in Osteoblasts

    Takeo Isozaki1, Yuzo Ikari1 and Tsuyoshi Kasama2, 1Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, 2Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Koutou-ku Tokyo, Japan

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation and joint destruction. Filgotinib is a selective small molecule inhibitor of JAK 1…
  • Abstract Number: 1529 • ACR Convergence 2020

    Differentially Expressed Chemokines and Cytokines in Peripheral Blood Mononuclear Cells (PBMCs) of Rheumatoid Arthritis (RA) Patients

    Noha Elemam1, Mahmood Hachim2, Suad Hannawi3 and Azzam Maghazachi4, 1University of Sharjah, Sharjah, United Arab Emirates, 2Mohammed Bin Rashid University Of Medicine and Health Sciences, Dubai, 3Ministry of Health and Prevention, Dubai, United Arab Emirates, 4University of Sharjah, Sharjah

    Background/Purpose: Rheumatoid arthritis (RA) is the most prevalent autoimmune disease, where various immune cells are associated such as monocytes, natural killer (NK) cells, B cells,…
  • Abstract Number: 1531 • ACR Convergence 2020

    Characterization of Cytokine/chemokine Profile in Patient-derived M1/ M2 Macrophages to Identify Biomarkers for Genetically-defined Systemic Autoinflammatory Diseases

    Farzana Bhuyan1, Adriana Almeida de Jesus2, Kim Johnson3, Jacob Mitchell4, Yan Huang5 and Raphaela Goldbach-Mansky5, 1NIH, bhetesda, MD, 2Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, 3NIH, NIAID, Bethesda, 4Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, 5NIH, Bethesda

    Background/Purpose: Genetic mutations in key regulatory molecules of the innate immune system cause autoinflammatory diseases through propagation of hyperinflammatory responses. Monocytes/ macrophages regulate inflammatory processes…
  • Abstract Number: 1948 • ACR Convergence 2020

    Identification of Small Molecules with Efficacy as Steroid Sparing Suppression of Chemokine and Cytokine Production by Rheumatoid Arthritis Fibroblast-like Synoviocytes

    Tadashi Hosoya1, Nikunj Shukla2, Yuya Fujita3, Shiyin Yao4, Fitzgerald Lao4, Hiroyuki Baba1, Shinsuke Yasuda5, Howard Cottam4, Dennis Carson4, Tomoko Hayashi4 and Mary Corr6, 1Department of Rheumatology, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, 2Moores Cancer Center, University of California San Diego, San Diego, CA, 3Department of Medicine, University of California San Diego, San Diego, CA, 4Moores Cancer Center, University of California San Diego, San Diego, 5Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, 6Department of Medicine, University of California San Diego, San Diego

    Background/Purpose: Target-based drug discovery has expanded our therapeutic armamentarium in the treatment of inflammatory and autoimmune diseases. Despite these advances, glucocorticoids (GC) remain reliable agents…
  • Abstract Number: 1952 • ACR Convergence 2020

    Activated Memory T Cells Produce Ligands That Cause NF-κB-dependent Inflammatory Activation of the Endothelium: Identification of Novel Therapeutic Targets

    Kim Jeucken1, Jan Piet van Hamburg1, Lotte Kocken1 and Sander Tas2, 1Amsterdam Rheumatology and Immunology Center (ARC), Department of Rheumatology and Clinical Immunology, Department of Experimental Immunology and Amsterdam Infection and Immunity Institute, Amsterdam UMC; location AMC, University of Amsterdam, Netherlands, Amsterdam, Netherlands, 2Amsterdam Rheumatology and Immunology Center (ARC), Department of Rheumatology and Clinical Immunology, Department of Experimental Immunology and Amsterdam Infection and Immunity Institute, Amsterdam UMC; location AMC, University of Amsterdam, Netherlands, Utrecht, Netherlands

    Background/Purpose: Endothelial cells (EC) are important contributors to inflammation via expression of inflammatory mediators, including cytokines, chemokines and adhesion molecules. Production of these inflammatory mediators…
  • Abstract Number: 0285 • ACR Convergence 2020

    CXCL13 Neutralization Reduces Neuropsychiatric Manifestations in MRL/lpr Mice

    Michelle Huang1, Ariel Stock1 and Chaim Putterman1, 1Albert Einstein College of Medicine, Bronx, NY

    Background/Purpose: Targeted treatments for neuropsychiatric systemic lupus erythematosus (NPSLE) remain challenging to develop due to the unclear pathogenesis of the disease. Our laboratory has previously…
  • Abstract Number: 0386 • ACR Convergence 2020

    Phase 1 Clinical Study of MGTA-145 in Combination with Plerixafor Shows Rapid Single-Day Mobilization and Collection of CD34+ Hematopoietic Stem Cells Without G-CSF

    John DiPersio1, Jonathan Hoggatt2, Steven Devine3, David Scadden2, Haley Howell4, Veit Schmelmer4, Glen Raffel4, Pat Falahee4, Kevin Goncalves4, William Savage4 and John Davis4, 1Washington University, Saint Louis, 2Massachusetts General Hospital, Boston, 3National Marrow Donor Program, Minneapolis, 4Magenta Therapeutics, Cambridge

    Background/Purpose: Autologous hematopoietic stem cell (HSC) transplantation is a recommended therapeutic option for selected patients with scleroderma and other autoimmune diseases. HSC transplant requires collection…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology